-
Pegaptanib sodium injection (brand name
Macugen) is an anti-angiogenic
medicine for the
treatment of
neovascular (wet) age-related
macular degeneration...
- injection) –
Pharmacologic stress agent for
myocardial perfusion scan
Macugen (pegaptanib sodium) – Anti-angiogenic –
marketed with
Gilead Sciences in...
-
Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan Macugen Odefsey Ranexa Sovaldi Stribild Tamiflu Truvada Tybost Veklury Vemlidy...
- markers, GFP-related fluorop****s, and a VEGF-binding
aptamer trade-named
Macugen has been
approved by the FDA for
treatment of
macular degeneration. Additionally...
-
Commercial products and
companies based on
aptamers include the drug
Macugen (pegaptanib) and the
clinical diagnostic company SomaLogic. The International...
-
anemia ****ociated with
chronic kidney disease (Roche, 2007)
Pegaptanib (
Macugen) – used to
treat neovascular age-related
macular degeneration (Pfizer,...
-
ranibizumab and
bevacizumab (known by a
variety of
trade names, such as
Macugen,
Avastin or Lucentis).
These inhibitors slow or stop the
formation of new...
- the
ophthalmology market through a
marketing agreement with
Pfizer over
Macugen (Pegaptanib) for Age-related
macular degeneration; however, acquisition...
- (CXCL2). An
example of an RNA
aptamer therapy includes Pegaptanib (aka
Macugen ® ), the only FDA-approved RNA
aptamer treatment.
Originally approved in...
- year, on
December 17, the
first intravitreal anti-VEGF drug
pegaptanib (
Macugen) was also
licensed by FDA for
treatment of wet age-related
macular degeneration...
